Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has maintained an Outperform rating on Avidity Biosciences (NASDAQ:RNA) and raised the price target from $40 to $45.
June 12, 2024 | 5:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group has maintained an Outperform rating on Avidity Biosciences and raised the price target from $40 to $45, indicating a positive outlook for the stock.
The raised price target and maintained Outperform rating from a reputable analyst group like Evercore ISI Group is likely to boost investor confidence and positively impact the stock price of Avidity Biosciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100